Katyna Borroto-Esoda
Gilead Sciences
Inc., Foster City
USA
Name/email consistency: high
- A comparison of the phenotypic susceptibility profiles of emtricitabine and lamivudine. Borroto-Esoda, K., Parkin, N., Miller, M.D. Antivir. Chem. Chemother. (2007)
- Baseline genotype as a predictor of virological failure to emtricitabine or stavudine in combination with didanosine and efavirenz. Borroto-Esoda, K., Waters, J.M., Bae, A.S., Harris, J.L., Hinkle, J.E., Quinn, J.B., Rousseau, F.S. AIDS Res. Hum. Retroviruses (2007)
- In vitro evaluation of the anti-HIV activity and metabolic interactions of tenofovir and emtricitabine. Borroto-Esoda, K., Vela, J.E., Myrick, F., Ray, A.S., Miller, M.D. Antivir. Ther. (Lond.) (2006)
- In vitro combination of amdoxovir and the inosine monophosphate dehydrogenase inhibitors mycophenolic acid and ribavirin demonstrates potent activity against wild-type and drug-resistant variants of human immunodeficiency virus type 1. Borroto-Esoda, K., Myrick, F., Feng, J., Jeffrey, J., Furman, P. Antimicrob. Agents Chemother. (2004)